Lectures

Anti-Herpes Agents: Thymidine Kinase Agents – Antiviral Drugs

by Pravin Shukle, MD
(1)

Questions about the lecture
My Notes
  • Required.
Save Cancel
    Learning Material 2
    • PDF
      Slide Anti-Virals Antimicrobials.pdf
    • PDF
      Download Lecture Overview
    Report mistake
    Transcript

    00:00 Let's move on in our discussion on antiviral agents.

    00:04 Let's focus now on those agents that are active against herpes.

    00:08 Specially let's focus on what we call "Thymidine Kinase Agents." Now these agents are important in the nucleic acid synthesis, portion of antiviral therapy.

    00:20 These thymidine kinase dependent agents include a acyclcovir and ganciclovir.

    00:26 They are active against HSV-1 and HSV-2 as well as varicella zoster.

    00:33 They have a very short half life and they are often administered three to five times a day.

    00:38 Now they are renally excreted as well.

    00:40 So we do adjust the dose in renal failure.

    00:43 Let's have a look where they work on our slide here.

    00:47 Now as we're going through the production of DNA, we have several steps.

    00:53 Now the host kinases are acted upon acyclcovir, and ganciclovir to prevent the diphosphate form of these agents from being produced.

    01:03 There are competitive substrates for DNA polymerase.

    01:06 And they lead to chain termination after incorporation into the DNA.

    01:12 Because they are defective agents, because they cause a defect in the actual DNA, you are unable to continue production of the DNA chain itself.

    01:23 That's why we call it chain termination.

    01:25 Now valacyclovir or Valtrex is a prodrug of acyclovir.

    01:31 So you can see here that I've pasted it in a little pink box above acyclcovir and ganciclovir.

    01:37 Now valacyclovir is able to achieve three to five times greater concentration levels and it also lasts lot longer.

    01:45 So for the most part it's replaced acyclovir as a means of therapy for certain types of disease.

    01:54 Pencyclovir actually works at the level of the DNA polymerase.

    01:57 So it doesn't cause chain termination.

    02:00 But what it does is it inhibits the production of DNA.

    02:04 Now famciclovir is converted to pencicyclovir by the liver.

    02:09 So once again I've put this prodrug form in a little pink box just under the pencyclovir.

    02:16 Ganicyclovir is a guanine derivative.

    02:20 Acyclovir is a guanosine derivative.

    02:23 So you can see, how they are acting at slightly different agents within the DNA molecule.

    02:29 Now when we're looking at these agents we know that they are inhibiting DNA polymerase inside cytomegalovirus and HSV alike.

    02:37 They are used in CMV retinitis and other CMV infections in patients who are immunocompromised as well.

    02:44 The toxicity of these agents include leukopenia, thrombocytosis and mucositis.

    02:52 Now there is another agent that is a prodrug that I just want to mention quickly.

    02:56 Valgancyclovir is a prodrug of ganciclovir.

    03:00 It has a very high bioavailability and a longer half life.

    03:04 So I anticipate that this is going to be something that will come on to the market quite strongly and start to replace the ganciclovir.

    03:11 Now when you take a look at all of these drugs and just sort of throw them into a class as a whole, the toxicities that we are concerned about is GI distress and nephrotoxicity.

    03:22 So these are present insignificant numbers enough that we have to keep a very close eye on them.

    03:28 With most antiviral agents, you are going to have some kind of neurological side effects.

    03:33 So we talk about headache, tremor, seizure, sometimes delirium as well.

    03:39 In terms of bone there was a concern that there would be an effect on bone marrow.

    03:45 But we are actually not seeing that play out in real life.

    03:48 How do agents develop resistance to drugs like acyclovir? It'll occur in two different ways.

    03:55 The first way is a change in the viral DNA polymerase.

    04:00 So obviously if there is a change in the target molecule, the drug won't work as well on that target molecule.

    04:05 The other way that it will work, is that some strains of virus actually lack the thymidine kinase that it's active upon.

    04:13 So this can be a viral specific phophorylation of acyclovir.

    04:18 And these agents will be cross resistant to each other.

    04:20 So you have to be aware that there is multiple ways of resistance and these are the two.

    04:26 Let's move on to Host Kinase Agents.

    04:30 Now host kinase agents are going to work on several areas of function.

    04:35 But mostly we're going to be focusing on the late protein synthesis processing of the virus.

    04:41 So cidofovir is activated by host cell kinsases.

    04:46 It's active in herpes simplex virus infection, cytomegalovirus, adenovirus and others.

    04:52 Now, it does not require viral kinase.

    04:57 It's active against many resistant viruses.

    05:00 The activity we use it against CMV retinitis and mucocutaneous herpes simplex virus.

    05:08 And sometimes we'll use it against genital warts as well.

    05:12 The toxicity that we're most concerned about is really nephrotoxicity.

    05:17 So this important to monitor renal function in patients on these agents.


    About the Lecture

    The lecture Anti-Herpes Agents: Thymidine Kinase Agents – Antiviral Drugs by Pravin Shukle, MD is from the course Antimicrobial Pharmacology. It contains the following chapters:

    • Anti-Herpes Agents: Thymidine Kinase Agents
    • Host Kinase Agents

    Included Quiz Questions

    1. Valacyclovir
    2. Acyclovir
    3. Cidofovir
    4. Pencyclovir
    5. Ganciclovir
    1. Pencyclovir
    2. Valacyclovir
    3. Valganiclovir
    4. Gangiclovir
    5. Acyclovir
    1. …bone marrow suppression.
    2. …GI distress.
    3. …seizures.
    4. …delirium.
    5. …nephrotoxicity.
    1. Longer half life with greater blood levels.
    2. Less resistance potential
    3. Crosses blood brain barrier
    4. Less GI side effects
    5. Does not require phosphorylation

    Author of lecture Anti-Herpes Agents: Thymidine Kinase Agents – Antiviral Drugs

     Pravin Shukle, MD

    Pravin Shukle, MD


    Customer reviews

    (1)
    5,0 of 5 stars
    5 Stars
    5
    4 Stars
    0
    3 Stars
    0
    2 Stars
    0
    1  Star
    0